Jefferies keeps USD 20 target for Iovance Biotherapeutics stock

Published on 10/20/2026 at 21:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter 2026 revenue reached USD 99.31 million. Iovance Biotherapeutics stock costs EUR 13.21 on October 20, 2026.

Revenue and reporting date

On October 12, 2026, Jefferies reiterated a USD 20.00 price target for Iovance.
Second-quarter 2026 revenue reached USD 99.31 million, up 65.70 percent year over year.
Iovance Biotherapeutics stock costs EUR 13.21 at Lang & Schwarz on October 20, 2026 at 9:14 p.m. CEST.

IOVA, US4622601007, Illustration mit AI erstellt.

On October 12, 2026, Jefferies analyst Andrew Tsai reiterated a Buy rating and a USD 20.00 price target for Iovance, as reported by Markets Insider. Second-quarter 2026 revenue reached USD 99.31 million, up 65.70 percent from the prior-year quarter, according to MarketBeat. At Lang & Schwarz, Iovance was trading at EUR 13.21 on October 20, 2026 at 9:14 p.m. CEST.

Revenue gives the stock a test

The second-quarter figure marked a clear change in scale for Iovance. MarketBeat reported that revenue had risen from USD 59.95 million in the same quarter of 2025, while the adjusted loss was USD 0.11 per share versus a USD 0.13 consensus estimate. That combination gives the company a stronger commercial reference point, but the loss profile remains material for valuation.

Stock stays below its yearly high

On Nasdaq, Iovance was trading at USD 14.82 on October 20, 2026 at 3:20 p.m. ET. Its market value was USD 6.7 billion, the price-to-earnings ratio was negative 20.32, and volume reached 7,594,320 shares on the same date. The 52-week range was USD 1.76 to USD 15.30, leaving the stock 3.14 percent below its high. Yahoo Finance also reported a 420.51 percent year-to-date gain through October 19, 2026.

What does the USD 20.00 target imply?

Using the Nasdaq price of USD 14.82 on October 20, 2026, Jefferies' USD 20.00 target from October 12, 2026 stood 34.95 percent above the price. The distance is large enough to matter, but it also reflects the uncertainty attached to a commercial-stage biotechnology company with a negative trailing valuation.

Next reporting date

Yahoo Finance lists November 5, 2026 as Iovance's next earnings date. Iovance develops tumor-infiltrating lymphocyte therapies and markets Amtagvi for previously treated advanced melanoma, according to the company's investor overview at Iovance Biotherapeutics.

Analyst target and valuation

The USD 20.00 Jefferies target sits above the USD 14.40 average target reported for the analyst group in Markets Insider's October 14, 2026 summary. MarketBeat counted nine buys, three holds and one sell among 13 firms, while its average target was USD 13.20.

At Lang & Schwarz, Iovance Biotherapeutics was trading at EUR 13.21 on October 20, 2026 at 9:14 p.m. CEST. On Nasdaq, the stock was trading at USD 14.82 on October 20, 2026 at 3:20 p.m. ET. The further course of trading is shown by the continuously updated real-time quote of Iovance Biotherapeutics stock.